Waxman reiterates scientific review request

Share this article:
Incoming Committee on Government Reform Chair Rep. Henry Waxman (D-CA) reiterated his request that the FDA conduct a thorough scientific review of phenylephrine's effectiveness at 10 mg as used in reformulated OTC decongestants, citing a DTC ad for Schering-Plough's Claritin-D indicating the company will not reformulate it.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Pharmaceutical

Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.